Aktueile sicherheitsaspekte der therapie mit topischen calcineurin- inhibitoren

Atopic dermatitis is a chronic-inflammatory skin disease with relapsing and remitting course, with a high prevalence (10-20 %) in children of western countries. For many decades, topical corticosteroids have been the mainstay of therapy for atopic dermatitis. After the introduction of calcineurin-inhibitors as a corticosteroid-free alternative, expectations were high. After the black-box-warning of the FDA, regarding potential theoretical risk for developing neoplasia under the treatment with calcineurin inhibitors, an uncertainty occurred among patients and physicians.